Ernexa Therapeutics Inc. (ERNA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 9M 18M 27M FY10: 25.3M FY11: 23.9M FY12: 24.1M FY13: 23.7M FY14: 26M FY15: 24.5M FY16: 22.3M FY17: 21.3M FY18: 23.3M FY19: 19.8M FY20: 5.8M FY22: 0 FY23: 68K FY24: 582K FY11 FY13 FY15 FY17 FY19 FY22 FY24

Gross Profit Annual

-200K 0 200K 400K 600K FY22: 0 FY23: -168K FY24: 486K FY22 FY23 FY24

Operating Income Annual

-120M -80M -40M 0 40M 80M 120M FY10: -325K FY11: -3.3M FY12: -1.1M FY13: -1.1M FY14: -4.7M FY15: -6.9M FY16: -2.3M FY17: -1.4M FY18: 203K FY19: -1.8M FY20: -7.2M FY21: -113.7M FY22: -33.2M FY23: -21.1M FY24: -15.7M FY25: -9.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-150M -100M -50M 0 50M 100M 150M FY10: -400K FY11: -3.4M FY12: -995K FY13: -1.1M FY14: -5M FY15: -7.2M FY16: -2.9M FY17: -1.1M FY18: -259K FY19: -2M FY20: -7.3M FY21: -122.5M FY22: -24.6M FY23: -21.7M FY24: -44.5M FY25: -14.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 90K 180K 270K FY22: 0 FY23: 236K FY24: 96K FY22 FY23 FY24

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY10: 2.8M FY11: 574K FY12: 2.2M FY13: 1.7M FY14: -6.4M FY15: -4.2M FY16: 23K FY17: 549K FY18: 1.4M FY19: 2.7M FY20: -8.1M FY21: -23.5M FY22: -21M FY23: -20.4M FY24: -15.8M FY25: -7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY10: 1.5M FY11: -1M FY12: 930K FY13: 632K FY14: -7.2M FY15: -5.2M FY16: -404K FY17: -179K FY18: 717K FY19: 2.6M FY20: -8.1M FY21: -23.6M FY22: -21.3M FY23: -20.4M FY24: -16.2M FY25: -7.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY10: 60.1M FY11: 60.4M FY12: 69K FY20: 17.6M FY21: 2.2M FY22: 3.1M FY23: 5.3M FY24: 910K FY25: 6.3M FY10 FY11 FY12 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q4 '13: -0.01 Q1 '14: -0.01 Q2 '14: -0.03 Q3 '14: -0.04 Q4 '14: -0.06 Q1 '15: -0.07 Q2 '15: -1.48 Q3 '15: -2.20 Q4 '15: -2.72 Q1 '16: -3.27 Q2 '16: -2.30 Q3 '16: -1.88 Q4 '16: -1.54 Q1 '17: -1.01 Q2 '17: -0.62 Q3 '17: -0.38 Q4 '17: -0.45 Q1 '18: -0.57 Q2 '18: -0.55 Q3 '18: -0.40 Q4 '18: -0.10 Q1 '19: -0.05 Q2 '19: -0.03 Q3 '19: -0.23 Q4 '19: -0.71 Q1 '20: -0.66 Q2 '20: -0.75 Q3 '20: -0.74 Q4 '20: -0.41 Q1 '22: -37.59 Q2 '22: -38.51 Q3 '22: -6.97 Q4 '22: -8.17 Q1 '23: -5.73 Q2 '23: -5.42 Q3 '23: -3.96 Q4 '23: -4.08 Q1 '24: -4.25 Q2 '24: -18.74 Q3 '24: -91.41 Q4 '24: -48.96 Q1 '25: -105.49 Q2 '25: -105.34 Q3 '25: -31.79 Q1 '14 Q3 '15 Q1 '17 Q3 '18 Q1 '20 Q3 '22 Q1 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.